The biological effect of a combination of platelet lysate and amniotic membrane in buccal epithelium culture

Purpose: To study the biological effect of a combination of platelet lysate and amniotic membrane, preserved by various techniques, on human buccal epithelium culture. Materials and methods. Human amnion transplants were preserved using 3 methods: silicate drying, lyophilization, cryopreservation. The blood of healthy volunteers was used as a source of platelets. Platelet-rich plasma (PRP) with a platelet content over 1000 thousand/mcl and more was isolated from the donors blood, frozen at -80 °С and defrosted at 0–4 °С to prepare platelet lysate. Growth-stimulating effect of the amnion transplants was studied in different groups: control group 1 — without amnion and without PRP lysate; control group 2 — PRP lysate without amnion; experimental group 1 — amnion without PRP lysate; experimental group 2 — amnion samples combined with PRP lysate. The study was carried out on the example of human buccal epithelium culture of 3–5 passages. The dynamics of cell growth was evaluated after 1, 2 and 3 days from the moment of seeding. The number of cells and their viability were evaluated using original methods based on vital cell staining and their examination in a fluorescent microscope. Results. All samples of preserved amnions were non-toxic and did not damage the structural and functional characteristics of the buccal epithelium. On the other hand, the use of amnion without PRP lysate did not have a growth-stimulating effect on cells. Among the amnion samples combined with PRP lysate, the combination of lyophilized amnion and PRP lysate was the most effective during the entire study period. Conclusions. Silicate drying, lyophilization and cryopreservation of the amniotic membrane makes it possible to obtain biocompatible and non-toxic transplants, based on human amnion. Lyophilized amnions are the most optimal for saturating PRP lysate. The combination of lyophilized amnion and PRP lysate stimulates cell growth in vitro without violating their structural integrity.

1. Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study. Lancet Global Health. 2021; 9 (2): e 144–60. doi.org/10.1016/S2214-109X(20)30489-7.

2. Shevlyuk N.N., Gatiatullin I.Z., Stadnikov A.A. Features of reparative histogenesis when using bioplastic materials. Journal of Anatomy and Histopathology. 2020; 9 (1): 86–93 (in Russian). doi:10.18499/2225-7357-2020-9-1-86-93

3. Kulikov A.N., Churashov S.V., Chernysh V.F., et al. Modern approaches to the problem of choosing a carrier for the cultivation of corneal stem cells in the treatment of limbal insufficiency. Ophthalmological journals. 2018; 11 (2): 48–56 (in Russian). doi:10.17816/OV11248-56.

4. Cabral J.V., Jackson C.J., Utheim T.P., Jirsova K. Ex vivo cultivated oral mucosal epithelial cell transplantation for limbal stem cell deficiency: a review. Stem Cell Res Ther. 2020; 11 (1): 301. doi:10.1186/s13287-020-01783-8

5. Cirman T., Beltram M., Schollmayer P., Rožman P., Kreft M.E. Amniotic membrane properties and current practice of amniotic membrane use in ophthalmology in Slovenia. Cell and Tissue Banking. 2013; 15 (2): 177–92. doi:10.1007/s10561-013-9417-6

6. Nejad A.R., Hamidieh A.A., Amirkhani M.A., Sisakht M.M. Update review on five top clinical applications of human amniotic membrane in regenerative medicine. Placenta. 2021; 103: 104–19. doi:10.1016/j.placenta.2020.10.026

7. Le Q., Deng S.X. The application of human amniotic membrane in the surgical management of limbal stem cell deficiency. Ocul Surf. 2019; 17 (2): 221–9. doi:10.1016/j.jtos.2019.01.003

8. McDaniel J.S., Wehmeyer J.L., Cornell L.E., Johnson A.J., Zamora D.O. Amniotic membrane allografts maintain key biological properties post SCCO2 and lyophilization processing. J. Biomater Appl. 2021; 35 (6): 592–601. doi:10.1177/0885328220952585

9. Walkden A. Amniotic membrane transplantation in ophthalmology: An updated perspective. Clin Ophthalmol. 2020; 14: 2057–72. doi:10.2147/OPTH.S208008

10. Borzenok S.A., Rolik O.I., Onishchenko N.A., Komakh Yu.A. On the possibility of improving the preservation of donor corneas by using regulatory peptides. Bulletin of transplantology and artificial organs. 2011; 13 (4): 101–5 (in Russian). doi:10.15825/1995-1191-2011-4-101-105

11. Gupta S., Paliczak A., Delgado D. Evidence-based indications of plateletrich plasma therapy. Expert Rev. Hematol. 2021; 14 (1): 97–108. doi:10.1080/17474086.2021.1860002

12. Amable P.R., Carias R.B., Teixeira M.V., et al. Platelet-rich plasma preparation for regenerative medicine: optimization and quantification of cytokines and growth factors. Stem Cell. Res Ther. 2013; 4 (3): 67. doi:10.1186/scrt218

13. Borovkova N.V., Makarov M.S., Andreev Yu.V., Storozheva M.V., Ponomarev I.N. Evaluation of the cytokine composition of blood serum and drugs based on human platelets. Molecular Medicine. 2021; 19 (3): 51–7 (in Russian). doi:10.29296/24999490-2021-03-08

14. Makarov M.S., Storozheva M.V., Konyushko O.I., Borovkova N.V., Khvatov V.B. Effect of concentration of Platelet-Derived Growth Factor on proliferative activity of human fibroblasts. Bull. Exp. Biol Med. 2013; 155: 576–80. doi:10.1007/s10517-013-2199-9

15. Abdelghany A.A., Bahrawy M.E., Alio J.L. Combined platelet rich plasma and amniotic membrane in the treatment of perforated corneal ulcers. Eur. J. Ophthalmol. 2022; 32 (4): 2148–52. doi:10.1177/11206721211049100

16. Davis A., Augenstein A. Amniotic allograft implantation for midface aging correction: A retrospective comparative study with platelet-rich plasma. Aesthetic Plast. Surg. 2019; 43 (5): 1345–52. doi:10.1007/s00266-019-01422-5

17. De la Puente P., Ludeña D. Cell culture in autologous fibrin scaffolds for applications in tissue engineering. Exp. Cell. Res. 2014; 322 (1): 1–11. doi:10.1016/j.yexcr.2013.12.017